Obagi Medical Products to Report Third Quarter 2008 Financial Results and Host a Conference Call on November 6

LONG BEACH, Calif.--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq:OMPI), today announced third quarter 2008 financial results will be released after market close on Thursday, November 6 and will be followed by an investor conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Investors interested in participating in the live call can dial (800) 762-8908 from the U.S. International callers can dial (480) 629-9031. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, November 27, by dialing (800) 406-7325 from the U.S., or (303) 590-3030 for international callers and entering confirmation code 3932987.

There also will be a simultaneous webcast available on the Investor Relations section of the Company's web site at www.obagi.com. For those unable to participate during the live broadcast, the webcast will be archived for 30 days.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics™ technologies, its products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. Obagi has introduced the following skin care products: Obagi Nu-Derm®, 1988; Obagi-C® Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi® Professional-C (a line of highly stable vitamin C serums), 2005; Obagi® Condition and Enhance for use with cosmetic procedures, 2006; Obagi ELASTIderm™ eye treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm® M.D. Systems for normal to dry skin, June 2007; and Obagi ELASTIderm™ Décolletage System, January 2008. Visit www.obagi.com for more information.